⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

AbbVie's risk disclosures remained largely stable between 2023 and 2024, with 27 of 31 total risk factors unchanged and no new risks added or removed. Four existing risk factors underwent substantive modifications, including updates to disclosures on pandemic impacts, information technology vulnerabilities, and international business exposure. These modifications suggest AbbVie refined its characterization of operational vulnerabilities rather than identifying fundamentally new risk categories.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🟡 Modified Public health outbreaks, epidemics or pandemics, such as the coronavirus (COVID-19), have had, and could in the future have, an adverse impact on AbbVie’s operations and financial condition. 🔒

🟡 Modified AbbVie depends on information technology and a failure of, or significant disruption to, those systems could have a material adverse effect on AbbVie's business. 🔒

🟡 Modified The international nature of AbbVie's business subjects it to additional business risks that may cause its revenue and profitability to decline. 🔒

🟡 Modified AbbVie is subject to cost-containment efforts and pricing pressures that could cause a reduction in revenues and operating earnings, and changes in the terms of rebate and chargeback programs, which are common in the pharmaceuticals industry, could have a material adverse effect on AbbVie's operations. 🔒

4 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →